Development of an LC-MS/MS method with protein G purification strategy for quantifying bevacizumab in human plasma

Huai Hsuan Chiu, I. Lin Tsai, Yen Shen Lu, Ching Hung Lin, Ching Hua Kuo

研究成果: 雜誌貢獻文章同行評審

18 引文 斯高帕斯(Scopus)

摘要

Biopharmaceutical products such as protein drugs and monoclonal antibodies (mAb) are currently of great interest with monoclonal antibody drugs being one of the fastest growing categories of biopharmaceutical products. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has gained high interest for measuring mAb drugs in biological samples in recent years due to its high selectivity. Bevacizumab is a humanized immunoglobulin G (IgG) mAb drug against human vascular endothelial cell growth factor A (VEGF-A). It is used for treating many types of cancers. Recent studies have indicated that clinical outcomes vary among patients treated with bevacizumab and produce various side effects, such as vascular disorders. In this study, we developed an LC-MS/MS method to quantify bevacizumab concentration. We selected readily available and economic materials for sample preparation to facilitate its wider use in clinical fields.—Protein G was used to trap bevacizumab from human plasma. In place of an extended stable isotope-labeled internal standard (SIL-IS), the IgG-based drug-IS tocilizumab was used because of its better calibration performance. The method was validated in terms of its precision, accuracy, linearity, and sensitivity. The accuracies which were expressed as percentage recoveries for three concentration levels were within 92.8 ± 3.2 to 112.7 ± 4.5%. Repeatability and intermediate precision in terms of peak area ratios were lower than 5.2 and 12.9% RSD, respectively. The application to patients’ sample measurements revealed a wide individual variability of drug concentrations, and the proposed simple and general method may facilitate personalized medicine for improving therapeutic efficacy and safety. [Figure not available: see fulltext.].

原文英語
頁(從 - 到)6583-6593
頁數11
期刊Analytical and Bioanalytical Chemistry
409
發行號28
DOIs
出版狀態已發佈 - 11月 1 2017

ASJC Scopus subject areas

  • 分析化學
  • 生物化學

指紋

深入研究「Development of an LC-MS/MS method with protein G purification strategy for quantifying bevacizumab in human plasma」主題。共同形成了獨特的指紋。

引用此